2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1880

Moderate Alcohol Consumption Is Associated with Lower Risk (and severity) of Chronic Widespread Pain: Results from a Population-Based Study
Abstract Number: 724

Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients
Abstract Number: 2051

Modification of Effects of Household Income and Homeownership By Block Group Poverty on Health Outcomes in a Cohort of African Americans with Rheumatoid Arthritis
Abstract Number: 1611

Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients
Abstract Number: 1328

Modulation of Natural IgM-Autoantibodies to Oxidative Stress-Related Neo-Epitopes on Apoptotic Cells in Newborns of Mothers with Anti-Ro Autoimmunity
Abstract Number: 1046

Modulatory Effect of Adiponectin on Apoptosis and Proliferation of Synovial Fibroblasts from Rheumatoid Arthritis Patients
Abstract Number: 750

Molecular Characterization of Systemic Sclerosis Esophageal Pathology Identifies Inflammatory and Proliferative Signatures with Few Fibrotic Markers
Abstract Number: 1756

Molecular Diagnosis Reveals a Surprising Prevalence of Limited Gpa Among Patients with Orbital Inflammatory Diseases
Abstract Number: 2929

Molecular Diagnostics for Patient Subsetting in Sjögren’s Syndrome
Abstract Number: 1749

Molecular Mechanisms Underlying 1,25(OH)₂D₃-Mediated Suppression of Th17 Cell Activity
Abstract Number: 1646

Molecular, Cellular and Histopathologic Assessment of Baseline Characteristics of Sixteen Subjects with Discoid Lupus Erythematosus Prior to Treatment with AMG 811 (anti-IFNγ)
Abstract Number: 1360

Monitoring Methotrexate and Leflunomide Treatment for Liver Toxicity: the Kaiser Permanente Experience
Abstract Number: 1307

Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients
Abstract Number: 1831

Monitoring Patients with Rheumatoid Arthritis in Routine Care – Experiences from a Treat-to-Target Strategy Using the Danbio Registry
Abstract Number: 1712

Monocytic Angiotensin and Endothelin Receptor Imbalance Determines Secretion of the Profibrotic Chemokine Ligand CCL18

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].